SELEXYS PHARMACEUTICALS CORP has a total of 20 patent applications. Its first patent ever was published in 2007. It filed its patents most often in EPO (European Patent Office), United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are TEVA BIOPHARMACEUTICALS USA INC, GHAYUR TARIQ and IPROTEOS S L.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 5 | |
#2 | United States | 3 | |
#3 | WIPO (World Intellectual Property Organization) | 3 | |
#4 | Canada | 2 | |
#5 | China | 2 | |
#6 | Japan | 2 | |
#7 | Colombia | 1 | |
#8 | Hungary | 1 | |
#9 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Peptides | |
#3 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Alvarez Richard | 18 |
#2 | Mcever Rodger P | 15 |
#3 | Rollins Scott | 15 |
#4 | Rother Russell | 11 |
#5 | Kawar Ziad S | 8 |
#6 | Kawar Ziad | 6 |
#7 | Ziad S Kawar | 2 |
#8 | Richard Alvarez | 2 |
#9 | Mcever Rodger | 1 |
Publication | Filing date | Title |
---|---|---|
US2009285812A1 | Methods of inhibiting the PSGL-1-mediated adhesion and chemokine-mediated migration with PSGL-1-specific antibodies | |
EP2097105A2 | Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases |